8-K: Shuttle Pharma CFO Resigns, Interim CEO Takes Dual Role

Shuttle Pharmaceuticals Holdings, Inc. announced the immediate resignation of CFO Timothy Lorber, with Interim CEO Christopher Cooper assuming the CFO role temporarily.

Summary

• Timothy Lorber resigned as Chief Financial Officer of Shuttle Pharmaceuticals Holdings, Inc. effective November 21, 2025.
• Mr. Lorber will assist with the transition of duties on a part-time basis (50% of base salary) through December 4, 2025, and remain available for consultation through February 8, 2026.
• In consideration for his transition assistance, Mr. Lorber will receive a retention bonus of $20,000 on November 21, 2025, and an additional $10,000 on December 4, 2025.
• A total of 39,854 unvested restricted stock units (RSUs) previously granted to Mr. Lorber will vest in their entirety on February 8, 2026, contingent upon his fulfillment of the transition plan.
• Christopher Cooper, the current Interim Chief Executive Officer, has assumed the role of Chief Financial Officer (Principal Financial Officer) effective November 21, 2025, while the company searches for a permanent CFO.
• The company and Mr. Lorber entered into a Separation Agreement and Mutual Release, which includes customary provisions for confidentiality, non-disparagement, cooperation, and return of company property.
• The agreement also includes mutual releases of claims, with specific exclusions for vested benefits, indemnification rights, and D&O insurance.
• Effective March 1, 2025, Mr. Lorber was not authorized to make any vendor payments without explicit board approval for each payment.

Sentiment

Score: 4

Explanation: The resignation of a CFO, especially with an interim replacement and the unusual detail about restricted payment authority, generally signals internal challenges and uncertainty. While the transition plan and mutual release are positive for managing the departure, the underlying reasons for the resignation and the interim nature of the replacement weigh negatively on sentiment. The company will need to demonstrate stability and a clear path forward with a permanent CFO.

Positives

• A structured transition plan is in place for the outgoing CFO, ensuring continuity of operations.
• The mutual release of claims between the company and the former CFO reduces potential future litigation risks.
• The company has an interim CFO (Christopher Cooper) immediately assuming the role, preventing a leadership vacuum in the finance department.
• The company explicitly commits to maintaining D&O insurance coverage for the former CFO through at least February 28, 2026, and upholding indemnification rights.

Negatives

• The immediate resignation of a Chief Financial Officer can signal instability or internal issues within the company.
• The need for the Interim CEO to also assume the CFO role suggests a lack of immediate internal succession planning for the CFO position.
• The detail about the former CFO not being authorized to make vendor payments without board approval since March 1, 2025, could indicate prior concerns or a loss of trust in the CFO's financial oversight.
• The company will incur costs related to the retention bonus ($30,000) and the accelerated vesting of 39,854 RSUs for the departing CFO.

Risks

• Operational Risk: The dual role of Interim CEO and CFO for Christopher Cooper could strain resources and attention, potentially impacting strategic initiatives or financial oversight.
• Reputational Risk: A CFO's resignation, especially with an interim replacement, can raise questions among investors and stakeholders about the company's stability and financial health.
• Talent Acquisition Risk: The company faces the challenge of finding a suitable permanent CFO, which could be difficult or lengthy, especially for a pharmaceutical company.
• Internal Control Risk: The disclosure that the former CFO required explicit board approval for vendor payments since March 1, 2025, suggests potential weaknesses in internal controls or a prior loss of confidence in the CFO's authority, which could have broader implications if not fully addressed.

Future Outlook

The company will conduct a search for a permanent Chief Financial Officer, indicating a temporary nature for Christopher Cooper's dual role. The structured transition plan for the outgoing CFO suggests an effort to maintain operational continuity during this period.

Management Comments

• Mr. Cooper will serve in this capacity while the Company conducts a search for a permanent Chief Financial Officer.
• The Parties agree that, reasonably following the Agreement Date, but no later than three business days, the Parties will mutually agree to the content of the announcement of Executives separation from the Company.

Industry Context

The pharmaceutical industry is highly regulated and often requires strong financial oversight and reporting. A change in CFO, especially with an interim appointment, can be viewed with caution by investors, as it might signal internal challenges or a shift in strategic direction. However, the structured transition and mutual release aim to mitigate potential disruptions. The specific mention of the former CFO's restricted payment authority since March 2025 could be a red flag, potentially indicating a need for tighter financial controls or a response to prior issues, which is a common theme in industries with high R&D costs and complex financial structures.

Comparison to Industry Standards

• The immediate appointment of an interim CFO from within the executive team (Interim CEO Christopher Cooper) is a common practice to ensure continuity during a CFO transition, aligning with industry standards for maintaining financial leadership.
• Providing a separation package including a retention bonus and accelerated RSU vesting for a departing executive, contingent on a transition plan, is standard practice in executive separations to ensure a smooth handover and mitigate potential disputes.
• The inclusion of mutual release of claims, non-disparagement, and confidentiality clauses in the separation agreement is standard for executive departures across industries, aiming to protect both the company and the individual.
• The explicit reaffirmation of indemnification rights and D&O insurance coverage for the departing CFO is crucial in highly litigious sectors like pharmaceuticals, aligning with best practices for executive protection.
• The disclosure that the former CFO's payment authority was restricted since March 2025 (requiring board approval for vendor payments) is an unusual and potentially concerning detail. While it could be a proactive measure for enhanced governance, it deviates from the typical autonomy granted to a CFO in most companies and might suggest underlying issues or a heightened need for internal controls, which could be below industry best practices if not properly explained or addressed.

Management Changes

Corporate Governance

Legal Proceedings

• The filing details a mutual release of claims between the company and the departing CFO, which aims to prevent future legal proceedings related to his employment or termination.

Stakeholder Impact

• Shareholders: May experience uncertainty due to the CFO's resignation and the interim appointment, potentially leading to short-term share price volatility. The detail about restricted payment authority could raise concerns about financial controls.
• Employees: Could perceive instability within senior management, potentially impacting morale or confidence in leadership.
• Customers/Suppliers: Unlikely to be directly impacted by this specific management change, but may monitor for broader signs of company stability.
• Creditors: May scrutinize the company's financial health and management stability more closely following the departure of a key financial officer.

Next Steps

• Timothy Lorber to provide part-time services through December 4, 2025, to assist with job duty transition.
• Timothy Lorber to remain available for reasonable consultation and inquiries through February 8, 2026.
• Shuttle Pharmaceuticals Holdings, Inc. will conduct a search for a permanent Chief Financial Officer.
• 39,854 unvested restricted stock units for Timothy Lorber will vest on February 8, 2026, contingent on his fulfillment of the transition plan.

Key Dates

Recommendation

The immediate resignation of a key executive like the CFO, coupled with the interim appointment of the CEO to fill the role, introduces a degree of uncertainty. The disclosure of the former CFO's restricted payment authority since March 2025 is a notable red flag, suggesting potential underlying issues or a need for tighter financial controls. While the structured transition and mutual release are positive for managing the departure, the overall situation warrants a cautious approach. Investors should hold to observe the company's progress in appointing a permanent CFO and to assess any further implications of the governance issues hinted at in the filing.

Keywords

Shuttle Pharmaceuticals, SHPH, CFO resignation, Chief Financial Officer, management change, corporate governance, separation agreement, restricted stock units, RSU vesting, interim CEO, Christopher Cooper, Timothy Lorber, pharmaceuticals, SEC filing, 8-K